Anabel Sorolla Bardaji
Grau: Doctor/a
asorolla(ELIMINAR)@irblleida.cat
ResearcherID: http://www.researcherid.com/rid/E-2546-2012
Publicacions
-
Das, A.; Pushparaj, C.; Bahi, N.; Sorolla, A.; Herreros, J.; Pamplona, R.; Vilella, R.; Matias-Guiu, X.; Marti, R. M.; Canti, C.
Functional expression of voltage-gated calcium channels in human melanoma
PIGMENT CELL & MELANOMA RESEARCH 25 200-212. .
-
Yeramian, Andree; Sorolla, Anabel; Velasco, Ana; Santacana, Maria; Dolcet, Xavier; Valls, Joan; Abal, Leandre; Moreno, Sara; Egido, Ramon; Casanova, Josep M.; Puig, Susana; Vilella, Ramon; Llombart-Cussac, Antonio; Matias-Guiu, Xavier; Marti, Rosa M.
Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway
INTERNATIONAL JOURNAL OF CANCER 130 967-978. .
-
Das, A; Sorolla, A; Herreros, J; Vilella, R; Matias-Guiu, X; Marti, RM; Canti, C
Role of voltage-gated calcium channels in the viability of melanoma
JOURNAL OF INVESTIGATIVE DERMATOLOGY 131 109-109. .
-
Yeramian, Andree; Santacana, Maria; Sorolla, Anabel; Llobet, David; Encinas, Mario; Velasco, Ana; Bahi, Nuria; Eritja, Nuria; Domingo, Monica; Oliva, Esther; Dolcet, Xavier; Matias-Guiu, Xavier
Nuclear factor-?B2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1a independent manner.
LABORATORY INVESTIGATION 91 859-871. .
-
Llobet, D.; Eritja, N.; Yeramian, A.; Pallares, J.; Sorolla, A.; Domingo, M.; Santacana, M.; Gonzalez-Tallada, F. J.; Matias-Guiu, X.; Dolcet, X.
The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.
EUROPEAN JOURNAL OF CANCER 46 836-850. .
-
Martinez-Alonso, M.; Llecha, N.; Mayorga, M. E.; Sorolla, A.; Dolcet, X.; Sanmartin, V.; Abal, L.; Casanova, J. M.; Baradad, M.; Yeramian, A.; Egido, R.; Puig, S.; Vilella, R.; Matias-Guiu, X.; Marti, R. M.
Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation.
Journal Of International Medical Research 37 1813-1822. .
-
Pallares, Judit; Santacana, Maria; Puente, Soraya; Lopez, Susana; Yeramian, Andree; Eritja, Nuria; Sorolla, Anabel; Llobet, David; Dolcet, Xavier; Matias-Guiu, Xavier
A review of the applications of tissue microarray technology in understanding the molecular features of endometrial carcinoma.
ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY 31 217-226. .
-
Ortega, Eugenia; Marti, Rosa M.; Yeramian, Andree; Sorolla, Anabel; Dolcet, Xavier; Llobet, David; Abal, Leandro; Santacana, Maria; Pallares, Judit; Llombart-Cussac, Antonio; Matias-Guiu, Xavier
Targeted therapies in gynecologic cancers and melanoma.
SEMIN DIAGN PATHOL 25 262-273. .
-
Velasco, Ana; Pallares, Judit; Santacana, Maria; Yeramian, Andre; Dolcet, Xavier; Eritja, Nuria; Puente, Soraya; Sorolla, Anabel; Llecha, Nuria; Matias-Guiu, Xavier
Loss of heterozygosity in endometrial carcinoma
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY 27 305-317. .
-
Velasco A; Pallares J; Santacana M; Yeramian A; Dolcet X; Eritja N; Puente S; Sorolla A; Llecha N; Matias-Guiu X
Loss of heterozygosity in endometrial carcinoma.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY 27 305-317. .
-
Llobet, D.; Eritja, N.; Encinas, M.; Llecha, N.; Yeramian, A.; Pallares, J.; Sorolla, A.; Gonzalez-Tallada, F. J.; Matias-Guiu, X.; Dolcet, X.
CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells.
ONCOGENE 27 2513-2524. .
-
Sorolla, A.; Yeramian, A.; Dolcet, X.; Perez de Santos, A. M.; Llobet, D.; Schoenenberger, J. A.; Casanova, J. M.; Soria, X.; Egido, R.; Llombart, A.; Vilella, R.; Matias-Guiu, X.; Marti, R. M.
Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines.
BRITISH JOURNAL OF DERMATOLOGY 158 496-504. .
Projectes
- Simultaneous targeting the partners in crime MYC and BRD4 in triple negative breast cancer
- DEVELOPMENT OF PRECISION THERAPIES FOR TRIPLE NEGATIVE BREAST CANCERS BASED ON CRISPR/CAS9 RIBONUCLEOPROTEINS.
- Ajuts contractació personal investigador predoctoral en formació (FI2022)
- Development of precision therapies for triple negative breast cancer based on CRISPR/Cas12a ribonucleoproteins
- Contrato Miguel Servet - Proyecto + RRHH
- EXPRESION DE CANALES DE CALCIO DE TIPO T EN NEOPLASIAS MELANOCÍTICAS BENIGNAS Y MALIGNAS. EVALUACION DE SU APLICICABILIDAD CLINICA COMO DIANAS TERAPEUTICAS EN EL MELANOMA
- Diseño y testaje de péptidos de interferencia para el tratamiento del cáncer de mama triple negativo